Keros Therapeutics, Inc.

KROS Nasdaq SEC CIK 1664710
Follow Keros Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $40M +180.5% vs same quarter last year
Net income $14.2M +294.4% vs same quarter last year
EPS, diluted $0.70 +488.9% vs same quarter last year
Operating cash flow $3.4M +4.3% vs same quarter last year
Revenue by quarter
$3M
$211.2M
$18.2M
$14.3M
$385K
$367K
$0
$40M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$244.1M$87M
FY24$3.6M−$187.4M
FY23$151K−$153M
FY22$0−$104.7M
FY21$20.1M−$58.7M
FY20$0−$45.4M
FY19$10M−$12.3M
FY18--
MarginsShare of revenue
  • Operating margin
  • Net margin
−150000%−100000%−50000%0%50000%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY2527.7%35.7%
FY24−5939%−5277.5%
FY23−112543.7%−101319.2%
FY22--
FY21−280.5%−292.3%
FY20--
FY19−105.6%−123.4%
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$200M−$100M$0$100M$200MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$106M
FY24−$162.8M
FY23−$127M
FY22−$71.3M
FY21−$63.2M
FY20−$37.2M
FY19−$16.3M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Keros Therapeutics
  • Healthcare median
−150000%−100000%−50000%0%50000%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearKeros TherapeuticsHealthcare median
FY2535.7%−30.6%
FY24−5277.5%−47%
FY23−101319.2%−58%
FY22-−80.4%
FY21−292.3%−71.8%
FY20-−62.2%
FY19−123.4%−46.2%
FY18-−49.6%